• In early February 2026, Twist Bioscience reported first-quarter fiscal 2026 revenue of US$103.7 million, up from US$88.71 million a year earlier, while maintaining a quarterly net loss of US$30.51 million and issuing raised revenue guidance for both the second quarter and full fiscal year 2026.
• An interesting feature of this update is how Twist’s silicon-based DNA synthesis platform and expanding customer base are underpinning its twelfth consecutive quarter of revenue growth and management’s focus on reaching adjusted EBITDA breakeven by late fiscal 2026.
• With shares rising over the past week, we’ll examine how Twist’s raised 2026 revenue outlook and DNA synthesis platform shape its investment narrative.

The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Twist Bioscience's Investment Narrative?

To own Twist Bioscience, you need to believe its silicon-based DNA synthesis platform can keep attracting more customers and applications while the company steadily narrows losses. The latest quarter supports that thesis: revenue of US$103.7 million was inline with the growth story, and management lifted both Q2 and full-year 2026 guidance to US$435–440 million, reinforcing revenue as the key short term catalyst. At the same time, the widened loss per share and ongoing net loss of US$30.51 million keep the path to adjusted EBITDA breakeven in late fiscal 2026 front and center. The sharp share price move after the update suggests the market is currently rewarding execution on growth, but it also raises the risk that any stumble on margins or guidance could hit sentiment harder than before.

However, one issue in the background may matter more than recent revenue beats. According our valuation report, there's an indication that Twist Bioscience's share price might be on the expensive side.

Exploring Other Perspectives

Three Simply Wall St Community fair values cluster between US$35.47 and US$42, while recent guidance-driven optimism and persistent losses highlight why opinions on Twist’s future performance can differ widely. This mix of community and fundamental views invites you to weigh both growth potential and execution risk before deciding how Twist fits your portfolio.

Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth as much as $42.00!

Build Your Own Twist Bioscience Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 52 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.